Compare Eastern Bankshares Inc. Common Stock (EBC) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eastern Bankshares Inc. Common Stock vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Eastern Bankshares Inc. Common Stock trades at $20.77 (market cap $4.79B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.13 (market cap $6.57B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and Eastern Bankshares Inc. Common Stock pays a 2.67% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eastern Bankshares Inc. Common Stock for 0 Days and Iovance Biotherapeutics Inc. Common Stock for 1 Days on average.
| EBC | IOVA | |
|---|---|---|
Market Cap | $4.79B | $6.57B |
Volume | 1,740,716 | 11,838,721 |
Sector | Financials | Health |
52-Week High | $23.65 | $14.82 |
52-Week Low | $16.73 | $1.81 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $5.07B | $6.50B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eastern Bankshares (EBC) trades at $20.96, down 0.85% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.71, net income margin of 33.47%, and recent Q2 2026 EPS beat. Analyst consensus is bullish with a $25.60 price target. Recent news highlights institutional buying and upcoming Q3 2026 earnings.
The outlook is positive given solid profitability, attractive valuation, and analyst support. Key risks include integration challenges from recent acquisitions and interest rate sensitivity. Upside potential exists if earnings momentum continues, but investors should monitor net cash flow trends and competitive pressures.
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eastern Bankshares Inc. Common Stock
Eastern Bankshares, Inc. is the holding company for Eastern Bank, a Massachusetts-based bank operating more than 125 branches across eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island, offering consumer and business banking along with wealth management through its Cambridge Trust divisions.
Read more on EBC →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
